$6.36
+0.46 (+7.80%)
Open$6.03
Previous Close$5.90
Day High$6.51
Day Low$5.90
52W High$7.85
52W Low$1.35
Volume—
Avg Volume328.8K
Market Cap104.45M
P/E Ratio3.50
EPS$2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+339.3% upside
Current
$6.36
$6.36
Target
$27.94
$27.94
$24.18
$27.94 avg
$39.76
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 60.69M | 8.10M | 7.51M |
| Net Income | 33.68M | -2,253,266 | -2,377,750 |
| Profit Margin | 55.5% | -27.8% | -31.6% |
| EBITDA | 33.33M | -3,375,106 | -3,186,219 |
| Free Cash Flow | — | -1,035,116 | -1,228,536 |
| Rev Growth | +155.8% | +18.0% | -0.1% |
| Debt/Equity | 2.29 | 0.78 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |